Vimarsana
Biggest News Aggregation in the World

Page 12 - Confidence Interval News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Confidence Interval. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Confidence Interval Today - Breaking & Trending Today

Tom Nguyen, MD: TAVR Explantation Outcomes with Balloon- vs Self-Expandable Valves - Vimarsana News

Tom Nguyen, MD: TAVR Explantation Outcomes with Balloon- vs Self-Expandable Valves

Tom Nguyen, MD, discusses a recent study he led comparing outcomes of TAVR explantation based on transcatheter heart valve type.

FDA Panel Votes in Favor of Abbott TriClip for Tricuspid Regurgitation - Vimarsana News

FDA Panel Votes in Favor of Abbott TriClip for Tricuspid Regurgitation

HCPLive is a comprehensive clinical news and information portal that provides physicians with up-to-date specialty and disease-specific resources designed to help them provide better care to patients. At HCPLive, you will find breaking news, video interviews with physician experts, in-depth conference coverage, finance and practice management updates, insight and analysis from physician contributors, and more.

Michelle Kittleson, MD, PhD: Need for Justice in Heart Transplant Allocation - Vimarsana News

Michelle Kittleson, MD, PhD: Need for Justice in Heart Transplant Allocation

Michelle Kittleson, MD, PhD, provides insight into the potential impact of a new risk score for heart transplant allocation as well as the need for more equitable cardiovascular care in the US.

New Risk Score Outperforms Current Model, Could Improve Heart Transplant Allocation - Vimarsana News

New Risk Score Outperforms Current Model, Could Improve Heart Transplant Allocation

A novel risk score developed by University of Chicago investigators outperformed conventional models in predicting death in heart transplant candidates, which could help bring the field closer to optimal and equitable allocation.

#VisualAbstract: Butantan-Dengue Vaccine effective in preventing symptomatic dengue - Vimarsana News

#VisualAbstract: Butantan-Dengue Vaccine effective in preventing symptomatic dengue

1. In this randomized controlled trial, the Butantan-Dengue Vaccine (Butantan-DV) was effective in the prevention of symptomatic, virologically confirmed dengue after two years, regardless of baseline serostatus. 2. Butantan-DV was effective against DENV-1 and DENV-2 serotypes across all age groups. Evidence Rating Level: 2 (Good) Study Rundown: Dengue is a mosquito-borne viral illness that can result in